After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Rakovina Therapeutics Inc. ('Rakovina” or the 'Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next ...

In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach ...

Roivant Sciences' 44% return highlights potential in its pipeline and partnerships. I maintain a cautious stance on RIOV ...

Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. Shares in biotech company Recursion ...

Merck announced plans to acquire Verona Pharma for roughly $10 billion. 1 As part of the agreement between the two companies, Merck will add Verona’s COPD treatment Ohtuvayre to its cardio-pulmonary ...

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

Ultragenyx Pharmaceutical Inc. shares plunged 30% as UX143 trial raises efficacy doubts. Click for more on RARE and my ...

DelveInsight’s Refractory Metastatic Melanoma pipeline report depicts a robust space with 4+ active players working to ...